WBR0808: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) (Created page with "{{WBRQuestion |QuestionAuthor={{Rim}} |ExamType=USMLE Step 1 |MainCategory=Physiology |SubCategory=Gastrointestinal |MainCategory=Physiology |SubCategory=Gastrointestinal |Mai...") |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 27: | Line 27: | ||
|AnswerC=Somatostatin | |AnswerC=Somatostatin | ||
|AnswerD=Secretin | |AnswerD=Secretin | ||
|AnswerE=H+ | |AnswerE=H+ | ||
|Approved=No | |Approved=No | ||
}} | }} | ||
Revision as of 21:38, 14 October 2013
| Author | [[PageAuthor::Rim Halaby, M.D. [1]]] |
|---|---|
| Exam Type | ExamType::USMLE Step 1 |
| Main Category | MainCategory::Physiology |
| Sub Category | SubCategory::Gastrointestinal |
| Prompt | [[Prompt::A researcher is studying the effect of a novel gastric inhibitory peptide (GIP) analog, GIP42, in mice. He notes the plasma concentration of compound X following the oral intake of GIP42 in experiment 1 and following intravenous (I.V.) administration of GIP42 in experiment 2. The graph below shows the evolution of plasma concentration of compound X during both experiments. Based on the researcher's findings, compound X most likely corresponds to which endogenous compound? |
| Answer A | AnswerA::Glucagon |
| Answer A Explanation | AnswerAExp:: |
| Answer B | AnswerB::Insulin |
| Answer B Explanation | AnswerBExp:: |
| Answer C | AnswerC::Somatostatin |
| Answer C Explanation | AnswerCExp:: |
| Answer D | AnswerD::Secretin |
| Answer D Explanation | AnswerDExp:: |
| Answer E | AnswerE::H+ |
| Answer E Explanation | AnswerEExp:: |
| Right Answer | RightAnswer:: |
| Explanation | [[Explanation:: Educational Objective: |
| Approved | Approved::No |
| Keyword | |
| Linked Question | Linked:: |
| Order in Linked Questions | LinkedOrder:: |
